Zymo Research Stands by Its Innovative cfDNA Technology in Response to Qiagen's Lawsuit

September 19, 2024 12:00 AM AEST | By Cision

Zymo Research Stands by Its Innovative cfDNA Technology in Response to Qiagen's Lawsuit — Image source: Kalkine Media

Recent News

Final Days to Submit Abstracts for the 2025 Lysosomal Disease Summit i...

5 big analyst AI moves: Apple downgraded, Nvidia gets a Sell rating, T...

End of an Era: Buffett to step down as Berkshire CEO

Leading Melbourne Chair Hire Company Confirmed That Event Planners Pre...

IRVINE, Calif., Sept. 18, 2024 /PRNewswire/ -- Zymo Research Corporation, a leader in innovative life science solutions, acknowledges the patent infringement lawsuit filed by Qiagen GmbH on August 20, 2024, at the US District Court for the Central District of California regarding its MAGicBead cfDNA isolation technology. Zymo Research respects intellectual property rights and is confident that this technology represents a significant advancement in nucleic acid purification.

"Our MAGic cfDNA purification system is a groundbreaking innovation," said Dr. Larry Jia, Founder and CEO of Zymo Research. "While this legal challenge places a significant burden on our resources as a small company, our commitment to the scientific community is stronger than ever."

For over 30 years, Zymo Research, a company of "Scientists for Scientists," has delivered innovative solutions to meet the evolving needs of researchers. Despite being a modestly sized company with around 250 employees, Zymo Research offers cutting-edge solutions from genetic, epigenetic, and microbiomic research tools to eco-friendly sample transport solutions. This is owed to prioritizing a culture of innovation, quality, and customer service.

"Our success is rooted in the trust of our customers and researchers worldwide," said Dr. Marc Van Eden, VP of Corporate Development. "We are committed to giving back to the community with the best, most innovative products."

Despite this legal challenge, Zymo Research remains focused on its mission of advancing life science with reliable solutions trusted by thousands of researchers globally and serves as a reminder of their unwavering commitment to science and the betterment of humanity.

About Zymo Research

Zymo Research, a privately owned biotech company founded in 1994, is a global leader in molecular tools for life sciences. Driven by the principle "The Beauty of Science is to Make Things Simple," Zymo Research is dedicated to developing innovative solutions that address complex scientific challenges. Known also as The Epigenetics Company, Zymo Research offers a comprehensive range of technologies, including solutions for sample collection, DNA/RNA purification, NGS library preparation, microbiomics, transcriptomics, epigenomics, genomics, and Next-Generation Sequencing (NGS) services.

Through scientific innovation, Zymo Research is committed to engineering sustainable biotech solutions that fundamentally change how life science research is conducted-- as demonstrated by their ambient temperature sample collection and transportation DNA/RNA Shield system, which eliminate cold chain logistics completely, thus reducing waste and the environmental footprint.

For more information, please visit www.zymoresearch.com and follow on Facebook, LinkedIn, X (Twitter), and Instagram.

Logo - https://mma.prnasia.com/media2/364743/Zymo_Research_Corp_Logo.jpg?p=medium600

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.